Véronique D’Hondt

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10

Multifactorial Approach to Predicting Resistance to Anthracyclines

Christine Desmedt, Angelo Di Leo, Evandro de Azambuja et al. · Journal of Clinical Oncology · 2011 · 187 citations

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García et al. · The Lancet · 2023 · 175 citations

Oncology, Cervical Cancer, Metronomic Therapy +6

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Paul Cottu, Véronique D’Hondt, Sylvain Dureau et al. · Annals of Oncology · 2018 · 160 citations · Full text

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Amit M. Oza, Ursula A. Matulonis, Susanne Malander et al. · The Lancet Oncology · 2018 · 123 citations

Medicine, Cancer Management, Gynecology +7